nodes	percent_of_prediction	percent_of_DWPC	metapath
Carvedilol—HIF1A—gall bladder—gallbladder cancer	0.0649	0.09	CbGeAlD
Carvedilol—NPPB—pancreas—gallbladder cancer	0.05	0.0693	CbGeAlD
Carvedilol—SELE—epithelium—gallbladder cancer	0.0379	0.0526	CbGeAlD
Carvedilol—VCAM1—epithelium—gallbladder cancer	0.0349	0.0484	CbGeAlD
Carvedilol—HIF1A—epithelium—gallbladder cancer	0.0336	0.0465	CbGeAlD
Carvedilol—GJA1—epithelium—gallbladder cancer	0.0326	0.0451	CbGeAlD
Carvedilol—VCAM1—pancreas—gallbladder cancer	0.0311	0.0431	CbGeAlD
Carvedilol—HIF1A—pancreas—gallbladder cancer	0.0299	0.0415	CbGeAlD
Carvedilol—GJA1—pancreas—gallbladder cancer	0.029	0.0402	CbGeAlD
Carvedilol—NDUFC2—epithelium—gallbladder cancer	0.0284	0.0393	CbGeAlD
Carvedilol—VEGFA—pancreas—gallbladder cancer	0.0229	0.0318	CbGeAlD
Carvedilol—SELE—liver—gallbladder cancer	0.0215	0.0298	CbGeAlD
Carvedilol—VCAM1—liver—gallbladder cancer	0.0198	0.0274	CbGeAlD
Carvedilol—HIF1A—liver—gallbladder cancer	0.019	0.0264	CbGeAlD
Carvedilol—GJA1—liver—gallbladder cancer	0.0185	0.0256	CbGeAlD
Carvedilol—ADRA1D—epithelium—gallbladder cancer	0.0168	0.0233	CbGeAlD
Carvedilol—SELE—lymph node—gallbladder cancer	0.0165	0.0229	CbGeAlD
Carvedilol—NDUFC2—liver—gallbladder cancer	0.0161	0.0223	CbGeAlD
Carvedilol—VCAM1—lymph node—gallbladder cancer	0.0152	0.021	CbGeAlD
Carvedilol—HIF1A—lymph node—gallbladder cancer	0.0146	0.0202	CbGeAlD
Carvedilol—VEGFA—liver—gallbladder cancer	0.0146	0.0202	CbGeAlD
Carvedilol—GJA1—lymph node—gallbladder cancer	0.0142	0.0196	CbGeAlD
Carvedilol—XDH—liver—gallbladder cancer	0.013	0.018	CbGeAlD
Carvedilol—NDUFC2—lymph node—gallbladder cancer	0.0123	0.0171	CbGeAlD
Carvedilol—VEGFA—lymph node—gallbladder cancer	0.0112	0.0155	CbGeAlD
Carvedilol—ADRA1A—epithelium—gallbladder cancer	0.00965	0.0134	CbGeAlD
Carvedilol—ADRA2C—pancreas—gallbladder cancer	0.00819	0.0114	CbGeAlD
Carvedilol—CYP1A1—epithelium—gallbladder cancer	0.00787	0.0109	CbGeAlD
Carvedilol—PTGS1—epithelium—gallbladder cancer	0.00692	0.00958	CbGeAlD
Carvedilol—ADRA2A—pancreas—gallbladder cancer	0.00654	0.00906	CbGeAlD
Carvedilol—ADRA1A—liver—gallbladder cancer	0.00547	0.00758	CbGeAlD
Carvedilol—ADRA2C—liver—gallbladder cancer	0.00521	0.00722	CbGeAlD
Carvedilol—CYP1A2—liver—gallbladder cancer	0.00452	0.00627	CbGeAlD
Carvedilol—CYP1A1—liver—gallbladder cancer	0.00446	0.00618	CbGeAlD
Carvedilol—CYP2C9—liver—gallbladder cancer	0.00429	0.00595	CbGeAlD
Carvedilol—ABCB1—epithelium—gallbladder cancer	0.00409	0.00567	CbGeAlD
Carvedilol—CYP2E1—liver—gallbladder cancer	0.00407	0.00564	CbGeAlD
Carvedilol—KCNH2—lymph node—gallbladder cancer	0.00405	0.00561	CbGeAlD
Carvedilol—ADRA2C—lymph node—gallbladder cancer	0.004	0.00554	CbGeAlD
Carvedilol—ABCB1—pancreas—gallbladder cancer	0.00364	0.00505	CbGeAlD
Carvedilol—CYP1A1—lymph node—gallbladder cancer	0.00342	0.00474	CbGeAlD
Carvedilol—CYP3A4—liver—gallbladder cancer	0.00327	0.00454	CbGeAlD
Carvedilol—CYP2D6—liver—gallbladder cancer	0.00322	0.00447	CbGeAlD
Carvedilol—ADRA2A—lymph node—gallbladder cancer	0.00319	0.00442	CbGeAlD
Carvedilol—PTGS1—lymph node—gallbladder cancer	0.00301	0.00417	CbGeAlD
Carvedilol—ABCB1—liver—gallbladder cancer	0.00232	0.00321	CbGeAlD
Carvedilol—VEGFA—VEGFR2 mediated cell proliferation—HRAS—gallbladder cancer	0.00229	0.00822	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	0.00224	0.00804	CbGpPWpGaD
Carvedilol—HIF1A—Signaling by NOTCH—TP53—gallbladder cancer	0.00218	0.00784	CbGpPWpGaD
Carvedilol—GJA1—Spinal Cord Injury—TP53—gallbladder cancer	0.00213	0.00763	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.00211	0.00759	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—NRAS—gallbladder cancer	0.00204	0.00733	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—ERBB4—gallbladder cancer	0.00198	0.0071	CbGpPWpGaD
Carvedilol—GJA1—EGF/EGFR Signaling Pathway—EGFR—gallbladder cancer	0.00196	0.00706	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—EGFR—gallbladder cancer	0.00186	0.00668	CbGpPWpGaD
Carvedilol—GJA1—EGF/EGFR Signaling Pathway—KRAS—gallbladder cancer	0.00186	0.00667	CbGpPWpGaD
Carvedilol—VEGFA—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.0018	0.00646	CbGpPWpGaD
Carvedilol—ABCB1—lymph node—gallbladder cancer	0.00178	0.00246	CbGeAlD
Carvedilol—VEGFA—SHP2 signaling—KRAS—gallbladder cancer	0.00176	0.00631	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—ERBB3—gallbladder cancer	0.00171	0.00614	CbGpPWpGaD
Carvedilol—ADRB2—Arf6 signaling events—EGFR—gallbladder cancer	0.00162	0.00582	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—KRAS—gallbladder cancer	0.0016	0.00576	CbGpPWpGaD
Carvedilol—GJA1—EGF/EGFR Signaling Pathway—HRAS—gallbladder cancer	0.00158	0.00567	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—NRAS—gallbladder cancer	0.00151	0.00544	CbGpPWpGaD
Carvedilol—VEGFA—SHP2 signaling—HRAS—gallbladder cancer	0.00149	0.00536	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—NRAS—gallbladder cancer	0.00143	0.00514	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—TP53—gallbladder cancer	0.00142	0.00512	CbGpPWpGaD
Carvedilol—VEGFA—Oncostatin M Signaling Pathway—HRAS—gallbladder cancer	0.00136	0.0049	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—KRAS—gallbladder cancer	0.0013	0.00468	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—BCL2—gallbladder cancer	0.00128	0.00461	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—NRAS—gallbladder cancer	0.00125	0.00449	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—KRAS—gallbladder cancer	0.00123	0.00442	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—ERBB4—gallbladder cancer	0.0012	0.00431	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—NRAS—gallbladder cancer	0.00118	0.00424	CbGpPWpGaD
Carvedilol—VCAM1—Cytokine Signaling in Immune system—HRAS—gallbladder cancer	0.00111	0.00398	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—TP53—gallbladder cancer	0.00109	0.00393	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—KRAS—gallbladder cancer	0.00108	0.00387	CbGpPWpGaD
Carvedilol—HIF1A—Cellular responses to stress—TP53—gallbladder cancer	0.00108	0.00387	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—ERBB2—gallbladder cancer	0.00107	0.00385	CbGpPWpGaD
Carvedilol—VEGFA—Focal Adhesion—BCL2—gallbladder cancer	0.00107	0.00384	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.00106	0.00382	CbGpPWpGaD
Carvedilol—SELE—Hemostasis—HRAS—gallbladder cancer	0.00105	0.00376	CbGpPWpGaD
Carvedilol—VEGFA—Focal Adhesion—ERBB2—gallbladder cancer	0.00104	0.00373	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—ERBB3—gallbladder cancer	0.00104	0.00372	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.00103	0.00371	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—KRAS—gallbladder cancer	0.00102	0.00365	CbGpPWpGaD
Carvedilol—VEGFA—EPH-Ephrin signaling—HRAS—gallbladder cancer	0.00101	0.00364	CbGpPWpGaD
Carvedilol—HIF1A—Disease—ERBB4—gallbladder cancer	0.000981	0.00352	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—NRAS—gallbladder cancer	0.000951	0.00342	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—EGFR—gallbladder cancer	0.000931	0.00334	CbGpPWpGaD
Carvedilol—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—gallbladder cancer	0.000915	0.00329	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—gallbladder cancer	0.000866	0.00311	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	0.000866	0.00311	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—EGFR—gallbladder cancer	0.000865	0.00311	CbGpPWpGaD
Carvedilol—VEGFA—Signaling by VEGF—HRAS—gallbladder cancer	0.000863	0.0031	CbGpPWpGaD
Carvedilol—HIF1A—Disease—ERBB3—gallbladder cancer	0.000848	0.00305	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.000818	0.00294	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—KRAS—gallbladder cancer	0.000817	0.00293	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—NRAS—gallbladder cancer	0.000815	0.00293	CbGpPWpGaD
Carvedilol—ADRA1B—LPA receptor mediated events—HRAS—gallbladder cancer	0.000748	0.00269	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—EGFR—gallbladder cancer	0.000743	0.00267	CbGpPWpGaD
Carvedilol—ADRA1B—AMPK Signaling—TP53—gallbladder cancer	0.000736	0.00264	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Breast Cancer Pathway—TP53—gallbladder cancer	0.000726	0.00261	CbGpPWpGaD
Carvedilol—VEGFA—Focal Adhesion—EGFR—gallbladder cancer	0.00072	0.00258	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.000716	0.00257	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—KRAS—gallbladder cancer	0.000702	0.00252	CbGpPWpGaD
Carvedilol—CYP1A1—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.000696	0.0025	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—ERBB4—gallbladder cancer	0.000687	0.00247	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—ERBB2—gallbladder cancer	0.000677	0.00243	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.000677	0.00243	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—BCL2—gallbladder cancer	0.000669	0.0024	CbGpPWpGaD
Carvedilol—ADRA1A—AMPK Signaling—TP53—gallbladder cancer	0.000654	0.00235	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—ERBB2—gallbladder cancer	0.00065	0.00234	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—NRAS—gallbladder cancer	0.000606	0.00218	CbGpPWpGaD
Carvedilol—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000602	0.00216	CbGpPWpGaD
Carvedilol—VCAM1—Adaptive Immune System—HRAS—gallbladder cancer	0.000597	0.00214	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—ERBB3—gallbladder cancer	0.000594	0.00213	CbGpPWpGaD
Carvedilol—VEGFA—Focal Adhesion—HRAS—gallbladder cancer	0.000578	0.00208	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—gallbladder cancer	0.000552	0.00198	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—gallbladder cancer	0.000552	0.00198	CbGpPWpGaD
Carvedilol—HIF1A—Disease—ERBB2—gallbladder cancer	0.000532	0.00191	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—gallbladder cancer	0.000522	0.00187	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—NRAS—gallbladder cancer	0.000515	0.00185	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—NRAS—gallbladder cancer	0.000495	0.00178	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—ERBB2—gallbladder cancer	0.000483	0.00174	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—EGFR—gallbladder cancer	0.000469	0.00169	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—gallbladder cancer	0.000467	0.00168	CbGpPWpGaD
Carvedilol—VEGFA—Cellular responses to stress—TP53—gallbladder cancer	0.000464	0.00167	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—EGFR—gallbladder cancer	0.000451	0.00162	CbGpPWpGaD
Carvedilol—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—gallbladder cancer	0.000444	0.00159	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—KRAS—gallbladder cancer	0.000443	0.00159	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—KRAS—gallbladder cancer	0.000426	0.00153	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—gallbladder cancer	0.000425	0.00153	CbGpPWpGaD
Carvedilol—HIF1A—Disease—NRAS—gallbladder cancer	0.000405	0.00145	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—gallbladder cancer	0.000402	0.00144	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—gallbladder cancer	0.000388	0.00139	CbGpPWpGaD
Carvedilol—KCNH2—Neuronal System—HRAS—gallbladder cancer	0.000385	0.00138	CbGpPWpGaD
Carvedilol—VEGFA—Axon guidance—HRAS—gallbladder cancer	0.000377	0.00135	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—ERBB2—gallbladder cancer	0.000372	0.00134	CbGpPWpGaD
Carvedilol—HIF1A—Disease—EGFR—gallbladder cancer	0.000369	0.00132	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—NRAS—gallbladder cancer	0.000368	0.00132	CbGpPWpGaD
Carvedilol—VCAM1—Immune System—HRAS—gallbladder cancer	0.000362	0.0013	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—NRAS—gallbladder cancer	0.000361	0.0013	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—gallbladder cancer	0.000353	0.00127	CbGpPWpGaD
Carvedilol—HIF1A—Disease—KRAS—gallbladder cancer	0.000348	0.00125	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—gallbladder cancer	0.000344	0.00124	CbGpPWpGaD
Carvedilol—ADRA1D—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—gallbladder cancer	0.000342	0.00123	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—EGFR—gallbladder cancer	0.000335	0.0012	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—gallbladder cancer	0.000334	0.0012	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—gallbladder cancer	0.000329	0.00118	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—gallbladder cancer	0.00032	0.00115	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—KRAS—gallbladder cancer	0.000316	0.00114	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—gallbladder cancer	0.000314	0.00113	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—KRAS—gallbladder cancer	0.00031	0.00112	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—ERBB4—gallbladder cancer	0.000297	0.00107	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ERBB4—gallbladder cancer	0.000297	0.00107	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—gallbladder cancer	0.000296	0.00106	CbGpPWpGaD
Carvedilol—HIF1A—Disease—HRAS—gallbladder cancer	0.000296	0.00106	CbGpPWpGaD
Carvedilol—ADRA1B—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—gallbladder cancer	0.000284	0.00102	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—NRAS—gallbladder cancer	0.000283	0.00102	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—TP53—gallbladder cancer	0.000276	0.000991	CbGpPWpGaD
Carvedilol—VEGFA—Developmental Biology—HRAS—gallbladder cancer	0.000269	0.000966	CbGpPWpGaD
Carvedilol—VEGFA—Hemostasis—HRAS—gallbladder cancer	0.000264	0.000948	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—EGFR—gallbladder cancer	0.000258	0.000927	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—ERBB3—gallbladder cancer	0.000257	0.000923	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ERBB3—gallbladder cancer	0.000256	0.000921	CbGpPWpGaD
Carvedilol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—gallbladder cancer	0.000252	0.000905	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—KRAS—gallbladder cancer	0.000244	0.000876	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—gallbladder cancer	0.000222	0.000796	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—TP53—gallbladder cancer	0.000217	0.000779	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—NRAS—gallbladder cancer	0.000213	0.000764	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—gallbladder cancer	0.000209	0.000752	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—NRAS—gallbladder cancer	0.000207	0.000745	CbGpPWpGaD
Carvedilol—HIF1A—Signaling Pathways—HRAS—gallbladder cancer	0.000207	0.000745	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—NRAS—gallbladder cancer	0.000199	0.000713	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB4—gallbladder cancer	0.000194	0.000695	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—EGFR—gallbladder cancer	0.000189	0.000679	CbGpPWpGaD
Carvedilol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—gallbladder cancer	0.000186	0.000668	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—KRAS—gallbladder cancer	0.000183	0.000657	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—KRAS—gallbladder cancer	0.000179	0.000641	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB4—gallbladder cancer	0.000176	0.000634	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB4—gallbladder cancer	0.000175	0.000628	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB4—gallbladder cancer	0.000173	0.00062	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—KRAS—gallbladder cancer	0.000171	0.000614	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB3—gallbladder cancer	0.000167	0.000601	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB4—gallbladder cancer	0.000163	0.000586	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—TP53—gallbladder cancer	0.000163	0.000584	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—NRAS—gallbladder cancer	0.000161	0.000579	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—ERBB2—gallbladder cancer	0.000161	0.000579	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—ERBB2—gallbladder cancer	0.000161	0.000577	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB4—gallbladder cancer	0.000161	0.000577	CbGpPWpGaD
Carvedilol—ADRA2B—Hemostasis—HRAS—gallbladder cancer	0.000156	0.000559	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB3—gallbladder cancer	0.000152	0.000548	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—TP53—gallbladder cancer	0.000152	0.000546	CbGpPWpGaD
Carvedilol—ADRB3—Signaling by GPCR—HRAS—gallbladder cancer	0.000152	0.000545	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB3—gallbladder cancer	0.000151	0.000543	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB3—gallbladder cancer	0.000149	0.000536	CbGpPWpGaD
Carvedilol—ADRA2C—Hemostasis—HRAS—gallbladder cancer	0.000145	0.000522	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB4—gallbladder cancer	0.000143	0.000513	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB3—gallbladder cancer	0.000141	0.000507	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB3—gallbladder cancer	0.000139	0.000499	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—KRAS—gallbladder cancer	0.000139	0.000499	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—NRAS—gallbladder cancer	0.000135	0.000485	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB4—gallbladder cancer	0.000133	0.000476	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—TP53—gallbladder cancer	0.000123	0.000443	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB3—gallbladder cancer	0.000123	0.000443	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—NRAS—gallbladder cancer	0.000123	0.000442	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—EGFR—gallbladder cancer	0.000123	0.000442	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—NRAS—gallbladder cancer	0.000123	0.00044	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—NRAS—gallbladder cancer	0.000122	0.000439	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—NRAS—gallbladder cancer	0.000122	0.000438	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—NRAS—gallbladder cancer	0.00012	0.000433	CbGpPWpGaD
Carvedilol—ADRA2A—Hemostasis—HRAS—gallbladder cancer	0.000118	0.000424	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—KRAS—gallbladder cancer	0.000116	0.000418	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB3—gallbladder cancer	0.000115	0.000412	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—NRAS—gallbladder cancer	0.000114	0.000409	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—EGFR—gallbladder cancer	0.000112	0.000403	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—NRAS—gallbladder cancer	0.000112	0.000403	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—EGFR—gallbladder cancer	0.000112	0.000401	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—EGFR—gallbladder cancer	0.000111	0.0004	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—EGFR—gallbladder cancer	0.000111	0.000399	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—EGFR—gallbladder cancer	0.00011	0.000394	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—KRAS—gallbladder cancer	0.000106	0.000381	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—KRAS—gallbladder cancer	0.000105	0.000379	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—KRAS—gallbladder cancer	0.000105	0.000378	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—KRAS—gallbladder cancer	0.000105	0.000377	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—ERBB2—gallbladder cancer	0.000105	0.000377	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—EGFR—gallbladder cancer	0.000104	0.000373	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—KRAS—gallbladder cancer	0.000104	0.000372	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—EGFR—gallbladder cancer	0.000102	0.000367	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—NRAS—gallbladder cancer	9.96e-05	0.000358	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling by GPCR—HRAS—gallbladder cancer	9.89e-05	0.000355	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—KRAS—gallbladder cancer	9.81e-05	0.000352	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—KRAS—gallbladder cancer	9.65e-05	0.000347	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—ERBB2—gallbladder cancer	9.56e-05	0.000343	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—ERBB2—gallbladder cancer	9.47e-05	0.00034	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—TP53—gallbladder cancer	9.37e-05	0.000337	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—TP53—gallbladder cancer	9.35e-05	0.000336	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—ERBB2—gallbladder cancer	9.35e-05	0.000336	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—NRAS—gallbladder cancer	9.26e-05	0.000333	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—EGFR—gallbladder cancer	9.08e-05	0.000326	CbGpPWpGaD
Carvedilol—ADRB1—Signaling by GPCR—HRAS—gallbladder cancer	9.01e-05	0.000324	CbGpPWpGaD
Carvedilol—ADRB3—Signaling Pathways—HRAS—gallbladder cancer	8.97e-05	0.000322	CbGpPWpGaD
Carvedilol—VEGFA—Signaling Pathways—HRAS—gallbladder cancer	8.95e-05	0.000321	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling by GPCR—HRAS—gallbladder cancer	8.93e-05	0.000321	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—ERBB2—gallbladder cancer	8.85e-05	0.000318	CbGpPWpGaD
Carvedilol—ADRB2—Signaling by GPCR—HRAS—gallbladder cancer	8.81e-05	0.000317	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—ERBB2—gallbladder cancer	8.71e-05	0.000313	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—KRAS—gallbladder cancer	8.57e-05	0.000308	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—EGFR—gallbladder cancer	8.43e-05	0.000303	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling by GPCR—HRAS—gallbladder cancer	8.34e-05	0.0003	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling by GPCR—HRAS—gallbladder cancer	8.21e-05	0.000295	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—NRAS—gallbladder cancer	7.98e-05	0.000287	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—KRAS—gallbladder cancer	7.97e-05	0.000286	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—ERBB2—gallbladder cancer	7.74e-05	0.000278	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling by GPCR—HRAS—gallbladder cancer	7.29e-05	0.000262	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—NRAS—gallbladder cancer	7.27e-05	0.000261	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—EGFR—gallbladder cancer	7.27e-05	0.000261	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—NRAS—gallbladder cancer	7.21e-05	0.000259	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—ERBB2—gallbladder cancer	7.19e-05	0.000258	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—NRAS—gallbladder cancer	7.12e-05	0.000256	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—KRAS—gallbladder cancer	6.87e-05	0.000247	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling by GPCR—HRAS—gallbladder cancer	6.77e-05	0.000243	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—NRAS—gallbladder cancer	6.73e-05	0.000242	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—EGFR—gallbladder cancer	6.63e-05	0.000238	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—NRAS—gallbladder cancer	6.63e-05	0.000238	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—EGFR—gallbladder cancer	6.57e-05	0.000236	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—EGFR—gallbladder cancer	6.48e-05	0.000233	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—KRAS—gallbladder cancer	6.26e-05	0.000225	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—KRAS—gallbladder cancer	6.2e-05	0.000223	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—EGFR—gallbladder cancer	6.13e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—KRAS—gallbladder cancer	6.12e-05	0.00022	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—TP53—gallbladder cancer	6.11e-05	0.000219	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—EGFR—gallbladder cancer	6.04e-05	0.000217	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—NRAS—gallbladder cancer	5.89e-05	0.000211	CbGpPWpGaD
Carvedilol—ADRA1D—Signaling Pathways—HRAS—gallbladder cancer	5.84e-05	0.00021	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—KRAS—gallbladder cancer	5.79e-05	0.000208	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—KRAS—gallbladder cancer	5.7e-05	0.000205	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—TP53—gallbladder cancer	5.56e-05	0.0002	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—TP53—gallbladder cancer	5.51e-05	0.000198	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—NRAS—gallbladder cancer	5.47e-05	0.000196	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—TP53—gallbladder cancer	5.44e-05	0.000196	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—EGFR—gallbladder cancer	5.36e-05	0.000193	CbGpPWpGaD
Carvedilol—ADRB1—Signaling Pathways—HRAS—gallbladder cancer	5.32e-05	0.000191	CbGpPWpGaD
Carvedilol—ADRA2B—Signaling Pathways—HRAS—gallbladder cancer	5.27e-05	0.000189	CbGpPWpGaD
Carvedilol—ADRB2—Signaling Pathways—HRAS—gallbladder cancer	5.21e-05	0.000187	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—TP53—gallbladder cancer	5.15e-05	0.000185	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—TP53—gallbladder cancer	5.07e-05	0.000182	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—KRAS—gallbladder cancer	5.07e-05	0.000182	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—EGFR—gallbladder cancer	4.98e-05	0.000179	CbGpPWpGaD
Carvedilol—ADRA2C—Signaling Pathways—HRAS—gallbladder cancer	4.93e-05	0.000177	CbGpPWpGaD
Carvedilol—ADRA1B—Signaling Pathways—HRAS—gallbladder cancer	4.85e-05	0.000174	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—KRAS—gallbladder cancer	4.71e-05	0.000169	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—TP53—gallbladder cancer	4.5e-05	0.000162	CbGpPWpGaD
Carvedilol—ADRA1A—Signaling Pathways—HRAS—gallbladder cancer	4.31e-05	0.000155	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—TP53—gallbladder cancer	4.18e-05	0.00015	CbGpPWpGaD
Carvedilol—ADRA2A—Signaling Pathways—HRAS—gallbladder cancer	4e-05	0.000144	CbGpPWpGaD
